news
-
5 February 2021Immunocore Announces Pricing of Upsized Initial Public Offering
Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. All ADSs sold in the offering were offered by Immunocore. The ADSs are expected to begin trading on The Nasdaq Global Select Market on February 5, 2021 under the ticker symbol “IMCR.” In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 9, 2021, subject to customary closing conditions.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC are acting as joint book-running managers for the offering.
A registration statement relating to these securities became effective on February 4, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 866 803 9204 or by email at prospectus-eq_fi@jpmchase.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at +1 877 821 7388 or by email at Prospectus_Department@Jefferies.com. For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European Economic Area or the United Kingdom.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
In any member state of the European Economic Area (the "EEA") this announcement and any offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129). In the United Kingdom, this announcement and any offering are only addressed to and directed at persons who are “qualified investors” within the meaning of the UK Prospectus Regulation (Regulation (EU) 2017/1129 as if forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons").
This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors.
Related
Immunocore announces closing of $75.0 Million Series C round
Immunocore announces dosing of first patient with fourth ImmTAC
First Site in Global Uveal Melanoma Patient Registry Now Open
Immunocore announces dosing of first patient with third ImmTAC® bispecific
Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
Immunocore appoints Bahija Jallal as Chief Executive Officer
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
Immunocore strengthens IP position in the field of TCR-based therapeutics
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
Immunocore Announces Management Change
Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards
Immunocore Announces Leadership Change
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline
Immunocore identifies second novel ImmTAC® in the GSK collaboration
Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016
Immunocore Appoints Paul Fry as Chief Financial Officer
Immunocore Ranked in the Sunday Times Hiscox Tech Track 100
Immunocore Wins Private UK Life Science Company of the Year at Biotech and Money Assembly and Awards
Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab
Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration
Immunocore expands its senior management team and opens US Office
Immunocore wins Biotech of the Year at the SCRIP Awards 2015